Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsASX:CUV -2.48%79 Debt-to-EBITDA is 0.01 as of Dec. 2025, which is 50% below its 10-year median of 0.02. GuruFocus rates ASX:CUV with a GF Score™ of 79/100 and a GF Value™ of A$17.77 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 295 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 99.66% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Clinuvel Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
ASX:CUV'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.1
Current: 0.01
During the past 13 years, the highest Debt-to-EBITDA Ratio of Clinuvel Pharmaceuticals was 0.10. The lowest was 0.01. And the median was 0.02.
ASX:CUV's Debt-to-EBITDA is ranked better than 99.66% of 295
companies
in the Biotechnology industry
Industry Median: 1.14
vs ASX:CUV: 0.01
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Clinuvel Pharmaceuticals Debt-to-EBITDA Related Terms
Clinuvel Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CUV vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Clinuvel Pharmaceuticals (ASX:CUV) has a Debt-to-EBITDA of 0.01 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Clinuvel Pharmaceuticals. This is 50% below median its historical median of 0.02. Over the past decade, Clinuvel Pharmaceuticals' Debt-to-EBITDA has ranged from 0.01 to 0.10. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #1 out of 295 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Clinuvel Pharmaceuticals' Debt-to-EBITDA too high?
Clinuvel Pharmaceuticals' current Debt-to-EBITDA of 0.01 is 50% below median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.10. The Biotechnology industry median Debt-to-EBITDA is 1.14. Clinuvel Pharmaceuticals' value of 0.01 is 99.1% below this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #1 out of 295 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #1 out of 295 companies for Debt-to-EBITDA. This places Clinuvel Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.14. Clinuvel Pharmaceuticals' value of 0.01 is 99.1% below this benchmark. Historically, Clinuvel Pharmaceuticals' own Debt-to-EBITDA has ranged from 0.01 to 0.10 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 1.14, Clinuvel Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 295 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current Debt-to-EBITDA of 0.01 is 99.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Clinuvel Pharmaceuticals. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Debt-to-EBITDA is 0.01, which is 50% below median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.77, compared to a current price of A$9.06 — trading 49% below its estimated fair value. The current Debt-to-EBITDA is 0.01, which is 50% below median its 10-year median of 0.02 and 99.1% below the Biotechnology industry median of 1.14. Clinuvel Pharmaceuticals' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Debt-to-EBITDA is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$9.06 is trading 49% below its estimated GF Value™ of A$17.77.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
Debt-to-EBITDA: 0.01 (50% below median its 10-year median of 0.02)
GF Value™: A$17.77 vs. price of A$9.06 (49% below fair value)
Industry Position: 99.1% below the Biotechnology median (#1 of 295)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
79GF Score
Get the complete analysis for ASX:CUV
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
